# Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

> **NCT04439695** · PHASE1 · COMPLETED · sponsor: **KBio Inc** · enrollment: 120 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Low dose
- **BIOLOGICAL:** Intermediate dose
- **BIOLOGICAL:** High dose
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04439695
- **Lead sponsor:** KBio Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-25
- **Primary completion:** 2021-02-25
- **Final completion:** 2021-07-28
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04439695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04439695, "Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04439695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*